Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system.

Cells from primary porcine hepatocytes (PPH) and the immortalized human hepatoma cell line C3A are both used in bioartificial liver support systems (BALSS). In this work the viability and metabolic capacity of PPH and C3A cells cultured in different media were compared. Also, because the cells come into direct or indirect contact with human blood components in BALSS, the effects of human complement on survival and functions of the cells was evaluated. For short-term culture, maintenance of PPH viability was essential for retention of P450IA1 activity (r = 0.882, p < 0.01) and effective ammonia clearance (r = -0.791, p < 0.01). When cell viability was below 60% P450IA1 activity could not be recorded and nitrogen elimination activity significantly diminished. In contrast to PPH, ammonia levels were markedly increased for C3A cells in all culture media tested (p < 0.01). Ammonia increase correlated with C3A viability (r = 0.896, p < 0.05). PPH metabolic function was superior to that of the C3A cell line when evaluated by P450IA1 activity, ammonia removal, and amino acid metabolism. When PPH were incubated in human plasma (HP) or human serum (HS) there was rapid and irreversible deterioration of viability occurring within 9 h. This toxic effect could be prevented by the inactivation of complement. When sodium citrate dissolved in dextrose was added to medium, there was considerable damage to both PPH and the C3A cell line. However, there was no demonstrable toxic effect when hepatic cells of either type were exposed to heparin. We conclude that PPH cultivated in complement-inactivated HP or HS are to be preferred to C3A for clinical application of BALSS, and that heparin should be preferred for anticoagulation in BALSS.

[1]  S. Nyberg,et al.  Immunoprotection of xenocytes in a hollow fiber bioartificial liver. , 1992, ASAIO journal.

[2]  B. Clement,et al.  Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads: a step toward a reliable bioartificial liver. , 1997, Transplantation.

[3]  P. Ferenci Brain dysfunction in fulminant hepatic failure. , 1994, Journal of hepatology.

[4]  L. Podestá,et al.  A Bioartificial Liver to Treat Severe Acute Liver Failure , 1994, Annals of surgery.

[5]  Roger Williams,et al.  Acute Liver Failure: Clinical experience with an extracorporeal liver assist device , 1996 .

[6]  D. Jefferson,et al.  Culturing hepatocytes and other differentiated cells , 1984, Hepatology.

[7]  M. Matsushita,et al.  A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. , 1991, ASAIO transactions.

[8]  Morgan Bp Physiology and Pathophysiology of Complement: Progress and Trends , 1995 .

[9]  E. Hertzberg,et al.  Proteoglycans and glycosaminoglycans induce gap junction synthesis and function in primary liver cultures , 1987, The Journal of cell biology.

[10]  A. Moorman,et al.  Hepatocyte heterogeneity in the metabolism of amino acids and ammonia. , 1992, Enzyme.

[11]  N. Sussman,et al.  The Hepatix extracorporeal liver assist device: initial clinical experience. , 1994, Artificial organs.

[12]  R. Butterworth,et al.  Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats , 1992, Hepatology.

[13]  A. Sheil,et al.  Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model. , 1996, The Australian and New Zealand journal of surgery.

[14]  J. Rozga,et al.  Plasma separation for artificial liver support , 1995, Journal of clinical apheresis.

[15]  J. Hoofnagle,et al.  Fulminant hepatic failure: Summary of a workshop , 1995, Hepatology.

[16]  M. Matsushita,et al.  Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. , 1993, ASAIO journal.

[17]  F. Villamil,et al.  Early clinical experience with a hybrid bioartificial liver. , 1995, Scandinavian journal of gastroenterology. Supplement.

[18]  P. Ferenci,et al.  Current concepts in the pathophysiology of hepatic encephalopathy , 1992, European journal of clinical investigation.

[19]  R. Williams,et al.  Bioartificial liver support: developments in hepatocyte culture and bioreactor design. , 1997, British medical bulletin.

[20]  J. Atkinson,et al.  Control of the complement system. , 1996, Advances in immunology.

[21]  J. Rozga,et al.  Artificial liver. Evolution and future perspectives. , 1995, ASAIO journal.

[22]  J. Fry,et al.  Influence of medium composition on 7-alkoxycoumarin O-dealkylase activities of rat hepatocytes in primary maintenance culture. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  Y. Sakai,et al.  Comparisons of Porcine Hepatocyte Spheroids and Single Hepatocytes in the Non-Woven Fabric Bioartificial Liver Module , 1996, The International journal of artificial organs.

[24]  A. Sheil,et al.  Evaluation of MTS, XTT, MTT and3HTdR incorporation for assessing hepatocyte density, viability and proliferation , 1996 .

[25]  M. Berry,et al.  Isolated Hepatocytes: Preparation, Properties and Applications , 1991 .

[26]  S. Enosawa,et al.  Examination of 7-ethoxycoumarin deethylation and ammonia removal activities in 31 hepatocyte cell lines. , 1996, Cell transplantation.

[27]  S. Nyberg,et al.  Evolution of the bioartificial liver: the need for randomized clinical trials. , 1993, American journal of surgery.

[28]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[29]  A. Sheil,et al.  Simple and reliable methods to assess hepatocyte viability in bioartificial liver support system matrices. , 1997, Artificial organs.